A preclinical study (Yang et al., 2006) and a phase I clinical trial (Lee et al., 2017) of in situ administrated DCs, which were genetically modified to overexpress CCL21 (CCL21-DC), demonstrated increased tumor antigen presentation, leading to systemic antitumor immunity. This evidence concerns the gene CCL21 and neoplasm.